Background Antiphospholipid syndrome (APS) is an acquired hypercoagulable condition
associated with antiphospholipid antibody (aPL) presence. Data on re-thrombosis following …

Objective To evaluate the clinical outcome after aPL (antiphospholipid antibodies)
disappearance in primary APS patients. Methods From a cohort of 70 patients with primary …

Introduction: Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia
associated with the presence of persistent antiphospholipid antibodies (aPL). Owing to …

Thrombotic manifestations of antiphospholipid syndrome are often a therapeutic dilemma
and challenge. Despite our increasing knowledge of this relatively new disease, many …

The presence of antiphospholipid antibodies has been shown to be related to an increased
risk of thrombotic events. In patients with definite antiphospholipid syndrome (APS), that is …

Although much progress has been made in the past 20 years on understanding the clinical
features of antiphospholipid syndrome (APS), investigation into its epidemiology has been …

Recommended treatment for patients with primary antiphospholipid syndrome (APS) after a
thrombotic event is long-term anticoagulation. Few patients with APS and previously positive …

Introduction Antiphospholipid syndrome (APS) is a pro-thrombotic autoimmune disease that
affects different vascular beds, with potential risk for recurrence. Systemic lupus …

Background/Purpose Long-term anticoagulation is the standard treatment for thrombotic
antiphospholipid syndrome (APS). However, in daily practice, the question of withdrawing …

Objective The objective of this paper is to assess the prevalence of the main clinical
manifestations and laboratory features at disease onset and during the ensuing 10 years of …